BSX stock forecast 2025 aligns with macro healthcare spending trends, where aging populations and increased procedural volumes underpin steady demand. Risk factors include regulatory changes and competitive product launches. On September 30, 2025, Boston Scientific Corporation presented at MEDevice Boston, featuring insights from Ann Roy, Vice President of Health Economics and Market Access, and Liza Davis, Vice President of R&D for Endoscopy, at the Boston Convention & Exhibition Center. Copyright © 2020-2025 Quiver Quantitative, Inc. All rights reserved. In medtech sector peer comparisons, BSX stock forecast 2025 ranks among the top quartile for ROE and ROI metrics. This competitive advantage stems from disciplined capital allocation and targeted M&A.